A new review of major clinical studies presented at a global hematology meeting shows that Yescarta®, a CAR T-cell therapy, continues to help people with relapsed or refractory large B-cell lymphoma live longer and experience meaningful improvements in health—even when they cannot undergo high-dose chemotherapy or a stem cell transplant.
Researchers looked at long-term results from two studies: ZUMA-7 and ALYCANTE. The data showed:
-
After two years, nearly two-thirds of patients were still alive, far better than older treatment outcomes.
-
Many patients saw their cancer stop growing or stay under control.
-
Over half had a strong response early in treatment, with some seeing their cancer become nearly undetectable.
-
Those who responded well often kept those benefits for a year or more.
Side effects were similar across both studies and considered manageable by doctors.
Quality-of-life scores dipped shortly after treatment but improved steadily within months and continued to rise over time.
Doctors say the results confirm that Yescarta can be a powerful early treatment option for patients whose lymphoma is difficult to treat with traditional therapies.